

Oracle Cloud Innovation Accelerator Program

Using Cloud to Fight Nicotine Addiction

- Smoking is the second most common cause of death globally¹ (~5 million deaths annually) and remains a major public health issue
- ~86% of lung cancer caused by tobacco
- 25% of the world's population smokes²
- Most anti-smoking drugs are only moderately effective in reducing symptoms of withdrawal and may cause undesirable side-effects (nausea, headaches, etc.)
- Nicotine is the major psychoactive agent in tobacco, causing addiction and binds mainly to $\alpha 4\beta 2$ nAChR³ (nicotine receptor in the brain)

1. "The health consequence of smoking: nicotine addiction", CDC, **1988**
2. "World Cancer Report 2014", WHO, **2014**
3. Dineley et al (2015) Trends Pharmacol Sci 36:96-108



Oracle Cloud Innovation Accelerator Program

Using Cloud to Fight Nicotine Addiction

- Researchers at Universities of Bath, Oxford-Brookes, Bristol and Milan are developing new molecules with improved effectiveness, specificity, and tolerability to be used as smoking cessation aids
- The team created a cluster of 5400 CPU cores in one hour and ran all the simulations successfully over 4 days, using ~600,000 CPU hours in total
- Running these simulations using Oracle's high performance cloud infrastructure saved the team over 3 months vs their traditional "on-premise" approach

